Marker Therapeutics (NASDAQ:MRKR) Research Coverage Started at Canaccord Genuity Group
Canaccord Genuity Group began coverage on shares of Marker Therapeutics (NASDAQ:MRKR – Free Report) in a report released on Wednesday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $8.00 price objective on the stock. Separately, Brookline Capital Management upgraded Marker Therapeutics to a “strong-buy” rating in a research note on Monday, February […]
Canaccord Genuity Group began coverage on shares of Marker Therapeutics (NASDAQ:MRKR – Free Report) in a report released on Wednesday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $8.00 price objective on the stock. Separately, Brookline Capital Management upgraded Marker Therapeutics to a “strong-buy” rating in a research note on Monday, February […]
